Search Results

Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced positive safety and immunogenicity data for MV-012-968, Meissa’s intranasal live attenuated RSV vaccine candidate, from a clinical study in RSV-naïve (seronegative) participants between the ages of six and 36 months.

The approvals come as Robert F. Kennedy Jr.—who has been critical of vaccines—takes leadership of the Department of Health and Human Services.

Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced interim clinical data of MV-012-968, Meissa’s intranasal live attenuated RSV vaccine candidate, from a Phase 1c study in RSV-naïve (seronegative) infants and young children.

Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced that Martin Moore, Ph.D., cofounder and Chief Scientific Officer of Meissa, spoke on a panel entitled, “Innovation in Vaccine Delivery,” at the Summit on the Future of COVID-19 Vaccines hosted by The White House Office for COVID-19 Response.

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development.

The postponed ACIP meeting comes barely a week after Robert F. Kennedy, Jr. was confirmed as Secretary of Health and Human Services, despite controversy regarding his anti-vaccine history.

Senators on the Health, Education, Labor and Pensions committee were critical of Kennedy’s long history as an anti-vaccine campaigner.

Without providing specific data, Sanofi on Thursday announced that the experimental vaccine did not significantly prevent invasive E. coli disease versus placebo.

Meissa Vaccines announced today the first seronegative participants have received MV-012-968, Meissa’s intranasal live attenuated RSV vaccine candidate, in a Phase 1c study in infants and young children.